HEALTH CARE:
BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Avalanche Biotechnologies Inc. develops gene therapies for the treatment of ophthalmologic disorders. The Company creates therapeutic protein for treatments of eye disease. Avalanche operates in the United States.
Market Cap | 1.108 Billion | Shares Outstanding | 97.478 Million | Avg 30-day Volume | 1.141 Million |
P/E Ratio | -10.5 | Dividend Yield | EPS | -1.28 | |
Price/Sales | Price cash flow ratio | 242.9 | Price free cash flow ratio | -19.4 | |
Book Value | 4.77 | Price to Tangible Book | 2.81 | Alpha | 0.02 |
Short Interest Ratio | % Short Interest to Float | R-squared | 0.074537 | ||
BETA | 1.71408 | 52-week High/Low | 26.98 / 7.36 | Stddev | 0.276266 |
Q3 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|---|---|---|---|---|---|
In top 10: | 4 | 8 | -50.0% | 1 (0.07%) | 4 (0.26%) | -75.0% |
Funds Holding: | 155 | 141 | 9.93% | 51 (3.35%) | 45 (2.92%) | 13.33% |
13F shares: | 94.886 Million | 80.872 Million | 17.33% | 48.535 Million | 39.645 Million | 22.42% |
% Ownership | 97.4871 | 49.8654 | 49.3736 | 1.0% | ||
New Positions: | 32 | 29 | 10.34% | 15 | 11 | 36.36% |
Increased Positions | 65 | 59 | 10.17% | 24 | 17 | 41.18% |
Closed Positions | 16 | 14 | 14.29% | 9 | 9 | 0.0% |
Reduced Positions | 38 | 38 | 0.0% | 10 | 15 | -33.33% |
Total Calls | 659.965 Thousand | 731.787 Thousand | -9.81% | 467.7 Thousand | 468.77 Thousand | -0.23% |
Total Puts | 414.556 Thousand | 235.093 Thousand | 76.34% | 332.086 Thousand | 156.8 Thousand | 111.79% |
PUT/CALL Ratio | 0.63 | 0.32 | 96.88% | 0.71 | 0.33 | 115.15% |
1 hedge funds and active managers as identified by whalewisdom.com through public filings. |
Please sign in first
18.6 Thousand total shares from 2 transactions
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
78,182 | 2021-01-15 | 2 | |
FISCHER LAURENT CEO AND DIRECTOR |
|
16,292 | 2021-01-15 | 4 |
|
18,822 | 2020-12-14 | 2 | |
|
0 | 2020-12-09 | 2 | |
SOPARKAR PETER CHIEF LEGAL OFFICER |
|
10,692 | 2020-08-17 | 2 |
|
274,442 | 2020-07-20 | 10 | |
|
0 | 2020-06-23 | 1 | |
|
0 | 2020-06-23 | 1 | |
|
0 | 2020-06-23 | 3 | |
|
0 | 2020-06-23 | 1 | |
|
0 | 2020-06-23 | 3 | |
PATTERSON LEONE D PRESIDENT |
|
110,488 | 2020-06-16 | 7 |
THEDINGA ANGELA CHIEF TECHNOLOGY OFFICER |
|
0 | 2020-02-21 | 2 |
OSBORNE AARON CHIEF MEDICAL OFFICER |
|
0 | 2020-02-20 | 1 |
LEUNG THOMAS CHIEF FINANCIAL OFFICER |
|
0 | 2020-02-20 | 1 |
|
0 | 2019-07-31 | 0 | |
|
0 | 2019-07-31 | 0 | |
CHENG JENNIFER C. GENERAL COUNSEL |
|
0 | 2019-02-14 | 0 |
|
0 | 2018-05-31 | 0 | |
SALZMAN AMBER PRESIDENT AND CEO |
|
0 | 2018-02-15 | 0 |
COUNTOURIOTIS ATHENA SVP, CHIEF MEDICAL OFFICER |
|
0 | 2018-02-15 | 0 |
|
398,991 | 2017-06-12 | 0 | |
BARONE SAMUEL B. SVP, CLINICAL DEVELOPMENT |
|
172,335 | 2017-02-09 | 0 |
RUSSO CARLO EVP AND CHIEF MEDICAL OFFICER |
|
0 | 2016-05-11 | 0 |
|
7,003,892 | 2016-05-11 | 0 | |
|
69,112 | 2016-02-29 | 0 | |
|
562,915 | 2016-02-12 | 0 | |
|
36,893 | 2016-02-12 | 0 | |
RUBIO ROMAN G. SVP, TRANSLATIONAL MEDICINE |
|
165,650 | 2016-02-12 | 0 |
BRAUN SHIRLEY VP, HUMAN RESOURCES |
|
161,140 | 2016-02-12 | 0 |
SWARTZBURG MICHAEL PRINCIPAL ACCOUNTING OFFICER |
|
82,113 | 2016-02-12 | 0 |
BAIN LINDA CHIEF FINANCIAL OFFICER |
|
41,930 | 2015-08-21 | 0 |
HULL HANS CHIEF EXECUTIVE OFFICER |
|
137,210 | 2015-08-21 | 0 |
CHALBERG THOMAS W. CHIEF EXECUTIVE OFFICER |
|
1,099,401 | 2015-06-10 | 0 |
|
200,000 | 2015-05-27 | 0 | |
|
No longer subject to file | 2015-04-13 | 0 | |
|
No longer subject to file | 2014-08-05 | 0 | |
DEERFIELD SPECIAL SITUATIONS FUND, L.P. DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P. |
|
No longer subject to file | 2014-08-05 | 0 |
VENROCK PARTNERS MANAGEMENT VI, LLC VENROCK HEALTHCARE CAPITAL PARTNERS LP |
|
2,365,471 | 2014-08-05 | 0 |
VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P. |
|
2,365,471 | 2014-08-05 | 0 |
VENROCK PARTNERS MANAGEMENT VI, LLC VENROCK HEALTHCARE CAPITAL PARTNERS LP |
|
0 | 2014-07-30 | 0 |
DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P. |
|
0 | 2014-07-30 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2021-01-19 20:33:27 -0500 | 2021-01-15 | P | 10,000 | $11.52 | a | 78,182 | direct | -3.592 | 0.0 | 1 | -3.592 | 2 | ||||
2021-01-19 20:32:40 -0500 | 2021-01-15 | P | 8,600 | $11.53 | a | 16,292 | direct | -3.592 | 0.0 | 1 | -3.592 | 2 | ||||
2020-12-16 17:10:23 -0500 | 2020-12-14 | J | 12,783 | a | 18,822 | direct | -2.9111 | -3.3832 | 1.5736 | 4 | -3.3832 | 6 | ||||
2020-12-11 21:12:26 -0500 | 2020-12-09 | A | 45,000 | a | 45,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |